person · Reporting owner
Hrynkow Sharon Hemond
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Chief Scientific Officer | December 02, 2021 | December 02, 2021 |
| Forward Industries, Inc.FORD · Entity 5540 | Director | September 08, 2025 | September 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyclo Therapeutics, Inc.
Report date December 02, 2021 · Filed December 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,350 |
Reported balance
After 2021-12-02 transaction · row 1
1 source rowRow 1 · 2021-12-02 · Purchase · Acquired 1,000 · Balance 19,350 |
Forward Industries, Inc.
Report date September 08, 2025 · Filed September 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.50 · Expires 2030-09-08 | Direct | 45,000 |
Reported balance
After 2025-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-08 · Grant · Acquired 45,000 · Balance 45,000 F2: Not applicable. F1: The grant of the Issuer's stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options are fully vested and granted under the Issuer's 2021 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The grant of the Issuer's stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options are fully vested and granted under the Issuer's 2021 Equity Incentive Plan.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2025 Filed Sep 11, 2025 20:00 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $18.50 | Not disclosed |
DisclosureSEC source: 0001683168-25-006865 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2030-09-08 F2 · price: Not applicable. F1 · derivative.exercise_date: The grant of the Issuer's stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors. The stock options are fully vested and granted under the Issuer's 2021 Equity Incentive Plan. Read SEC document |
| June 01, 2025 Filed Jun 3, 2025 20:03 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 12,147 | Not disclosed Strike: $6.37 | Not disclosed |
DisclosureSEC source: 0001683168-25-004189 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,147 Underlying: Common Stock · 12,147 shares Expires 2030-06-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The stock options shall vest on June 1, 2026, subject to continued service as a director on the vesting date. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 20:03 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 24,010 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001683168-24-006839 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,010 Underlying: Common Stock · 24,010 shares Expires 2029-10-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The stock options shall vest on October 1, 2025, subject to continued service as a director on the vesting date. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:02 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 110,803 | Not disclosed Strike: $0.76 | Not disclosed |
DisclosureSEC source: 0001683168-23-006931 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,803 Underlying: Common Stock · 110,803 shares Expires 2028-10-01 F2 · price: Not applicable. F1 · derivative.exercise_date: The stock options vest on October 1, 2024, subject to continued service as a director on the vesting date. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:02 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 41,580 | Not disclosed Strike: $1.03 | Not disclosed |
DisclosureSEC source: 0001683168-23-003859 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,580 Underlying: Common Stock · 41,580 shares Expires 2028-05-31 F2 · price: Not applicable. F1 · derivative.exercise_date: The stock options vest six months from the Transaction Date, subject to continued service as a director on the vesting date. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:03 UTC | Forward Industries, Inc. FORD · Entity 5540 | PurchaseCommon Stock | 4,855 | $1.16 | $5,631.80 |
DisclosureSEC source: 0001683168-22-008580 · ownership.xml · nonDerivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,855 Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:03 UTC | Forward Industries, Inc. FORD · Entity 5540 | PurchaseCommon Stock | 5,000 | $1.13 | $5,650.00 |
DisclosureSEC source: 0001683168-22-008580 · ownership.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:01 UTC | Forward Industries, Inc. FORD · Entity 5540 | GrantStock Options (Right to Buy) · Derivative | 31,095 | Not disclosed Strike: $1.68 | Not disclosed |
DisclosureSEC source: 0001683168-22-001156 · ownership.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,095 Underlying: Common Stock · 31,095 shares Expires 2027-02-16 F2 · price: Not applicable. F1 · derivative.exercise_date: The stock options vest one year from the Transaction Date, subject to continued service as a director on the vesting date. Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 16:54 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 1,000 | $4.98 | $4,980.00 |
DisclosureSEC source: 0001437749-21-027716 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,350 Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 19:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 23,800 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001437749-21-021213 · rdgdoc.xml · derivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,800 Underlying: Common Stock · 23,800 shares Expires 2031-08-27 F1 · derivative.exercise_date: The option vests over a four year period in equal monthly installments. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 13:25 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 1,000 | $7.46 | $7,460.00 |
DisclosureSEC source: 0001437749-21-007617 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,350 Read SEC document |
| January 13, 2021 Filed Jan 25, 2021 20:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-001218 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,350 Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:04 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 1,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-20-025287 · rdgdoc.xml · derivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2025-12-11 F1 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:04 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-025287 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,350 F1 · price: The reported securities consist of 1,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:06 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 200,000 | $0.10 | $20,000.00 |
DisclosureSEC source: 0001437749-20-008577 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 635,000 Read SEC document |
| September 27, 2019 Filed Sep 30, 2019 11:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-019214 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435,000 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 11:52 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 7,500 | $0.25 | $1,875.00 |
DisclosureSEC source: 0001437749-19-015271 · rdgdoc.xml · nonDerivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,000 Read SEC document |
| August 01, 2019 Filed Aug 2, 2019 11:52 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 2,500 | $0.24 | $600.00 |
DisclosureSEC source: 0001437749-19-015271 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,500 Read SEC document |
| July 31, 2019 Filed Jul 31, 2019 18:30 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 2,500 | $0.25 | $625.00 |
DisclosureSEC source: 0001437749-19-015071 · rdgdoc.xml · nonDerivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Read SEC document |
| July 31, 2019 Filed Jul 31, 2019 18:30 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 7,500 | $0.24 | $1,800.00 |
DisclosureSEC source: 0001437749-19-015071 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,500 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:35 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 40,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-011248 · rdgdoc.xml · derivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2024-11-30 F1 · price: The reported securities consist of 40,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:35 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-011248 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,000 F1 · price: The reported securities consist of 40,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 10:28 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 40,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001437749-18-022634 · rdgdoc.xml · derivative · entry 2 Hrynkow Sharon Hemond · CIK 0001745677 · SVP for Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2025-12-21 F1 · price: The reported securities consist of 40,000 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 10:28 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 40,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-022634 · rdgdoc.xml · nonDerivative · entry 1 Hrynkow Sharon Hemond · CIK 0001745677 · SVP for Medical Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 F1 · price: The reported securities consist of 40,000 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.